生物医学研究新闻英文配音

In 2017, Kymriah and Yescarta as chimeric antigen receptor (CAR) T-cell immunotherapies were approved by the U.S. Food and Drug Administration (FDA) to treat B-lymphocytic leukemia, marking a new era of cell-based therapy for cancer patients and a landmark achievement in drug development. CARs are synthetic receptors that redirect lymphocytes to recognize and eliminate target cells. T cells engineered to express CARs (CAR-T) have shown unprecedent treatment efficacy in patients with B cell leukemia. However, cytokine release syndrome (CRS), a notorious side effect induced by CAR-T cells, can be lethal to patients. To date, how CAR-T therapy causes CRS remains unclear.

Recently, a research group from the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CAMS),provided a new answer to this key question c